Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efanesoctocog Alfa Post-Marketing Observational Safety Study in Hemophilia A in Japan
jRCT1031240049Recruiting
- Sponsor
- Sanofi
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Primary safety assessment of efanesoctocog alfa in clinical practice. Started Jun 2024; status: recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT1031240049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240049.